ArticlemedRxiv : the preprint server for health sciences2025
Trends in Industry-Sponsored Research Funding to Orthopaedic Surgeons in the U.S. from 2017-2024.
Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Orthopaedic injuries and musculoskeletal (MSK) diseases limit function, reduce quality of life, and carry substantial socioeconomic burdens. Because federal support for orthopaedic research is disproportionately low and volatile, industry-sponsored research funding (ISRF) can provide additional support to advance clinical care. We performed an analysis of ISRF directed to orthopaedic surgeons Principal Investigators (PIs) between 2017 and 2024 using the Centers for Medicare & Medicaid Services Open Payments database. Payments were aggregated per PI, then stratified by subspecialty, study phase (pre-clinical vs registered clinical trial), and sponsoring company. In doing so, we found that orthopaedic surgeon PIs received $395.7 million in ISRF during this eight-year span; each year this averaged $49.5 million from 106 companies to 956 investigators, with the median ISRF $14,121 to each PI. Across the study period, approximately 5% of ISRF supported pre-clinical work, and 20% was tied to registered clinical trials. Surgeons who received ISRF also accepted higher general (non-research) industry payments than their non-research peers ($69,441 vs $8,363; p<0.001). Together, these results show that ISRF provides an avenue to conduct research and augment other sources of funding.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.